Search Results

Whether you were diagnosed with cervical cancer following routine screening or after experiencing symptoms, deciding what to do next can feel overwhelming. The right treatment for you may depend on a variety of factors, including the type and stage of your cervical cancer, any potential side effects, and your personal preferences. While there’s a lot…

Human papillomavirus (HPV) is a sexually transmitted infection that is spread through intimate, skin-to-skin contact. HPV comprises a group of more than 150 related viruses that thrive in the cells found on the skin’s surface or other moist (mucosal) surfaces. Some HPV types cause common skin warts or low-risk genital warts. Other HPV types are…

Retrospective Observational Study of Hormone Receptor Positive (HR+) and HER2-low (IHC1+ or 2+ with ISH negative) and HER2- ultralow (IHC0 with membrane staining) Metastatic Breast Cancer (MBC) Brief Summary: This is a multicenter retrospective observational study in participants with HR+ HER2-low and HER2-ultralow MBC. ENHERTU treatment should have been received on or after September 2022…

An Interventional Phase 3, Double-Blind, Randomized Study to Evaluate Efficacy and Safety of PF-08634404 in Combination With Chemotherapy Versus Pembrolizumab in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer MOA: F-08634404 is a PD-1xVEGF bispecific antibody. Key Eligibility Criteria: LA (Stage IIIB/C) or met (Stage IV) squamous or…

ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer – CA266-0003 MOA: Pumitamig (BMS-986545/BNT327) is a bispecific antibody targeting PD-L1 and VEG-F. Key Eligibility Criteria: Previously untreated, histologically confirmed recurrent or metastatic colorectal adenocarcinoma,…

A randomized, Phase 3, open-label study to evaluate PF-08046054/SGN-PDL1V vs Docetaxel in adult participants with previously-treated programmed cell death ligand (PD-L1) positive non-small cell lung cancer (NSCLC) MOA: F-08046054/SGN-PDL1V is an anti-PD-L1 ADC with a MMAE payload Key Eligibility Criteria: Histologically or cytologically documented unresectable Stage IIIB, IIIC, IV NSCLC not eligible for definitive chemoradiotherapy.…